21 MAR 2005

Peptide T1 (139-141) H_2N-A-L-K-COOH

Peptide T2 (146-148) H_2N-H-I-R-COOH

Peptide T3 (136-138) H_2N-F-D-K-COOH

Peptide T4 (71-75) H_2N-I-I-A-E-K-COOH

Peptide T5 (62-69) H_2N-E-N-G-E-C-A-Q-K-COOH

Peptide T6 (84-91) H_2N-I-D-A-L-N-E-N-K-COOH

Peptide T7 (9-14) H_2N-G-L-D-I-Q-K-COOH

Peptide T8 (142-145) H_2N-A-L-P-M-COOH

Peptide T9.T10, T11 (61-67,-68,-69) H_2N-W-E-N-G-E-C-A,-Q,-K,-COOH

Peptide T12 (125-135) H_2N-T-P-E-V-D-D-E-A-L-E-K-COOH

Peptide T13 (1-8) H_2N-L-I-V-T-Q-T-M-K-COOH

Peptide T14 (142-148) = T8 (142-145) + T2 (146-148) H_2N-A-L-P-M-H-I-R-COOH

Peptide T15 (78-82) H_2N-I-P-A-V-F-K-COOH

Peptide T16 (15-20) H_2N-V-A-G-T-W-Y-COOH

Peptide T17 (92-99,100) H_2N-V-L-V-L-D-T-D-Y-K,-K-COOH

Peptide T18 (125-138) = T12 (125-135) + T3 (136-138) H_2N-T-P-E-V-D-D-E-A-L-E-K-F-D-K-COOH

Peptide T19 (25-40) H_2N-A-A-S-D-I-S-L-L-D-A-Q-S-A-P-L-R-COOH

Peptide T20, T21 (61, 62-69):S-S:(149-162)

H_2N-W,-E-N-G-E-C-A-Q-K-COOH

|

H_2N-L-S-F-N-P-T-Q-L-E-E-Q-C-H-I-COOH

Peptide T22 (21-40) H_2N-S-L-A-M-A-A-S-D-I-S-L-L-D-A-Q-S-A-P-L-R-COOH

Peptide T23 (41-60) H_2N-V-Y-V-E-E-L-K-P-T-P-E-G-D-L-E-I-L-L-Q-K-COOH

Peptide T24 (149-162) H_2N-L-S-F-N-P-T-Q-L-E-E-Q-C-H-I-COOH

Fig. 1



A
seric and mucosal anti-BLG IgE (log1/dil)
4.5
3.5
2.5
1.5
0.5
saline
TTHBLG
F2
F(7+9)
oral tolerance induction groups
B
foot pad increment (mm)
0.3
0.2
0.1
0
Saline
TTHBLG
F2
F(7+9)
oral tolerance induction group
C
proliferative response
100000
80000
60000
40000
20000
0
5
2.5
0.5
0.1
BLG stimulation (mg/ml)
Saline
TTHBLG
F2
F(7+9)
D
proliferative response (cpm)
20000
15000
10000
5000
0
250
50
10
2
PHA stimulation (µg/ml)
Saline
TTHBLG
F2
F(7+9)

Fig. 2